Pyxis Reports Positive Phase 1 Data for MICVO Head and Neck Cancer Therapy
Pyxis Oncology announced favorable data from a Phase 1 study of its antibody-drug conjugate MICVO in head and neck cancer, prompting a planned pivotal trial in 2027.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day